Genital Diseases, Female  >>  erlotinib  >>  Phase 2
Welcome,         Profile    Billing    Logout  

9 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
erlotinib / Generic mfg.
NCT00031993: Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix

Completed
2
51
US
erlotinib hydrochloride, CP-358,774, erlotinib, OSI-774, laboratory biomarker analysis
National Cancer Institute (NCI)
Cervical Squamous Cell Carcinoma, Recurrent Cervical Cancer
11/05
 
NCT00126542: Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Completed
2
35
US
bevacizumab, anti-VEGF humanized monoclonal antibody, anti-VEGF monoclonal antibody, Avastin, rhuMAb VEGF, erlotinib hydrochloride, CP-358,774, erlotinib, OSI-774, laboratory biomarker analysis
National Cancer Institute (NCI)
Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
01/07
04/10
NCT00030485: Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer

Completed
2
Canada
erlotinib hydrochloride
National Cancer Institute (NCI), NCIC Clinical Trials Group
Endometrial Cancer
04/07
04/07
NCT00130520: Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer

Completed
2
40
US
bevacizumab, Avastin, erlotinib, Tarceva
University of Arizona, Genentech, Inc.
Ovarian Neoplasms
01/10
05/10
NCT00059787: Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma

Completed
2
56
US
paclitaxel, Anzatax, Asotax, TAX, Taxol, carboplatin, Carboplat, CBDCA, JM-8, Paraplat, Paraplatin, erlotinib, CP-358,774, OSI-774
National Cancer Institute (NCI)
Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
05/10
05/10
NCT00520013: Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors

Completed
2
60
US
bevacizumab, Avastin, rhuMAB VEGF, erlotinib, Tarceeva, paclitaxel, Taxol, carboplatin, Paraplatin
Dana-Farber Cancer Institute, Genentech, Inc., Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Massachusetts General Hospital
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Papillary Serous Mullerian Tumor, Clear Cell Mullerian Tumor
10/10
11/13
NCT01003938: Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer

Terminated
2
6
US
Topotecan, Topotecan hydrochloride, Hycamtin, Erlotinib, Tarceva
NYU Langone Health, OSI Pharmaceuticals
Ovarian Cancer
09/12
12/12
NCT00063895: Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck

Completed
1/2
80
US
erlotinib hydrochloride, CP-358,774, erlotinib, OSI-774, pharmacological study, pharmacological studies, pharmacogenomic studies, Pharmacogenomic Study, laboratory biomarker analysis
National Cancer Institute (NCI)
Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IIIA Non-small Cell Lung Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx
10/05
 
NCT00217529: Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Completed
1/2
US
pegfilgrastim, carboplatin, docetaxel, erlotinib hydrochloride
Fred Hutchinson Cancer Center
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
11/05
 

Download Options